Navigation Links
Drug Fails to Slow Progression of Atherosclerosis
Date:3/17/2009

Pactimibe also was associated with more risk of major heart problems, study finds

TUESDAY, March 17 (HealthDay News) -- A drug that blocks an enzyme involved in the accumulation of cholesterol does not reduce the progression of atherosclerosis, thickening and stiffening of the arteries, but increases the risk of major cardiovascular events, according to an international study.

Researchers assessed the safety and efficacy of the drug pactimibe, which inhibits an enzyme known as ACAT, in 892 people with a family history of high cholesterol, which is associated with an increased risk of atherosclerosis. The participants, from 40 clinics in the United States, Canada, Europe, South Africa and Israel, were randomly selected to take either 100 milligrams a day of pactimibe or a placebo, in addition to standard lipid-lowering therapy.

The researchers assessed the participants' atherosclerosis at the start of the study and 12, 18 and 24 months later using ultrasound to measure carotid intima-media thickness (CIMT), a measurement of the thickness of the inner wall of a major artery. Increasing thickness indicates increasing plaque in the artery.

After six months, levels of "bad" low-density lipoprotein (LDL) cholesterol had increased by 7.3 percent among people taking pactimibe and by 1.4 percent among those taking the placebo. This increase disappeared after participants stopped taking the drug.

There was no difference between the two groups in progression of maximum CIMT, but average CIMT progressed significantly in the pactimibe group within one year, compared with minor CIMT progression in the placebo group, the study found.

Compared with people in the placebo group, those in the pactimibe group suffered more serious events (10 percent vs. 7.7 percent) and more cardiovascular events (6.3 percent vs. 3.4 percent) and had a higher rate for the composite of cardiovascular death, heart attack and stroke (2.3 percent vs. 0.2 percent).

Dr. Marijn C. Meuwese, of the Academic Medical Center in Amsterdam, The Netherlands, and colleagues wrote that in people with a family history of cholesterol, "pactimibe had no effect on atherosclerosis as assessed by changes in maximum CIMT compared with placebo but was associated with an increase in mean CIMT as well as increased incidence of major cardiovascular events."

The findings from this and previous studies lessen "the promise and further development of this class of drugs (ACAT inhibitors) for cardiovascular prevention," they concluded.

The study is in the March 18 issue of the Journal of the American Medical Association.

More information

The U.S. National Heart, Lung, and Blood Institute has more about atherosclerosis.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Federal research plan to determine nanotech risks fails to deliver
2. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Experimental Drug Fails Against Heart Failure
5. NSAID Drug Therapy Fails to Ease Back Pain
6. MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements
7. Steroid Fails to Ease Meningitis in Trials
8. Pharmaceutical market fails pregnant women; and more
9. Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
10. Post-Op Chemo Fails to Boost Survival in Stomach Cancers
11. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Fails to Slow Progression of Atherosclerosis
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... direct measurement of corrosive ions found in power plant water and steam. , ... such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring ...
(Date:3/28/2017)... ... ... A minimally invasive porcelain veneer is increasing in popularity ... Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive dentistry, ... and technicians that create these veneers. , According to National Board for ...
(Date:3/28/2017)... Atlantic City, NJ (PRWEB) , ... March 28, ... ... annual American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was ... partners, and their team of professional staff discussed strategies for preventing outbreaks among ...
(Date:3/28/2017)... ... 2017 , ... Thank you to all who attended Capio Partners Winter 2017 ... was exclusive to providers and offered an opportunity to collaborate and network with healthcare ... Grand Hyatt where attendees gathered for a lively discussion on trends and issues that ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... -- To mark the end of Save Your Vision Month, ... digital imaging solutions, will showcase Canon eye care devices during ... New York,s Jacob Javits Center from March 30 ... the American Optometric Association, is observed annually in March to ... exams. In recognition of this observance, Canon U.S.A. ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology: